Design Therapeutics (DSGN) Retained Earnings (2020 - 2026)
Design Therapeutics (DSGN) reported Retained Earnings of -$314.6 million for Q1 2026, down 28.48% on a YoY basis from -$439.9 million in Q1 2025, and down 78174.94% sequentially from $403000.0 in Q4 2025.
Design Therapeutics (DSGN) Retained Earnings (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Retained Earnings data on file, last reported at -$314.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 28.48% year-over-year to -$314.6 million; the trailing twelve-month figure through Mar 2026 stood at -$314.6 million (down 28.48% YoY), and the FY2025 full-year result was $403000.0, up 100.18% from the prior year.
- Retained Earnings retreated to -$314.6 million in Q1 2026, from $403000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $403000.0 in Q4 2025 to a low of -$314.6 million in Q1 2026.
- A 5-year average of -$129.5 million and a median of -$150.0 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings soared 101.85% in 2023 and sank 366574.19% in 2024, its largest moves.
- Tracing DSGN's Retained Earnings over 5 years: stood at -$3.4 million in 2022, then soared by 101.85% to $62000.0 in 2023, then sank by 366574.19% to -$227.2 million in 2024, then soared by 100.18% to $403000.0 in 2025, then sank by 78174.94% to -$314.6 million in 2026.
- Business Quant data shows DSGN's Retained Earnings at -$314.6 million in Q1 2026, $403000.0 in Q4 2025, and -$281.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -314.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -314.64 Mn |
| Dec 31, 2025 | 403,000.00 |
| Sep 30, 2025 | -281.00 Mn |
| Jun 30, 2025 | -264.01 Mn |
| Mar 31, 2025 | -244.90 Mn |
| Dec 31, 2024 | -227.21 Mn |
| Sep 30, 2024 | -213.56 Mn |
| Jun 30, 2024 | -200.50 Mn |
| Mar 31, 2024 | -167,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | -165.80 Mn |
| Jun 30, 2023 | -150.00 Mn |
| Mar 31, 2023 | -130.10 Mn |
| Dec 31, 2022 | -3.36 Mn |
| Sep 30, 2022 | -3.86 Mn |
| Jun 30, 2022 | -2.32 Mn |
| Mar 31, 2022 | -1.32 Mn |
| Dec 31, 2021 | -244,000.00 |
| Sep 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -12,000.00 |